Search company, investor...
Solana Surgical company logo

Solana Surgical

solanasurgical.com

Stage

Acquired | Acquired

Valuation

$0000 

Revenue

$0000 

About Solana Surgical

Solana Surgical is a global extremity orthopedic company that develops breakthrough solutions to restore motion while relieving pain for patients and improving surgical outcomes for surgeons. Based in Memphis, Tennessee, and having launched its first product in 2011, Solana Surgical's goal is to advance the science in the foot, ankle and hand markets by meeting unmet needs with innovative new products.

Headquarters Location

6363 Poplar Ave Ste. 312

Memphis, Tennessee, 38119,

United States

855-214-1860

Missing: Solana Surgical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Solana Surgical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Solana Surgical Patents

Solana Surgical has filed 12 patents.

The 3 most popular patent topics include:

  • Bone fractures
  • Foot
  • Orthopedic surgical procedures
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/20/2018

5/19/2020

Bone fractures, Orthopedic surgical procedures, Skeletal system, Foot, Skeletal disorders

Grant

Application Date

8/20/2018

Grant Date

5/19/2020

Title

Related Topics

Bone fractures, Orthopedic surgical procedures, Skeletal system, Foot, Skeletal disorders

Status

Grant

Latest Solana Surgical News

Wright Medical Group, Inc. Completes Acquisition of OrthoPro, LLC

Feb 5, 2014

February 05, 2014 04:00 PM Eastern Standard Time MEMPHIS, Tenn.--( BUSINESS WIRE )--Wright Medical Group, Inc. (NASDAQ: WMGI) today announced that it has completed its acquisition of OrthoPro, LLC (OrthoPro), a high-growth extremities company. Along with the acquisition of Solana Surgical announced last week, this transaction adds complementary extremity product portfolios to further accelerate growth opportunities in Wright’s global Extremities business. Wright previously announced plans on January 30, 2014 to acquire OrthoPro for an upfront purchase price of $32.5 million paid in cash at closing, plus milestone payments of up to an additional $3.5 million in cash, contingent upon the achievement of certain revenue-based milestones. Wright will provide additional information on the financial impact of the OrthoPro and Solana Surgical transactions on its fourth quarter 2013 earnings call, which is scheduled for February 24, 2014. About Wright Medical Wright Medical Group, Inc. is a specialty orthopaedic company that provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients’ lifestyles. The company is the recognized leader of surgical solutions for the foot and ankle market, one of the fastest growing segments in medical technology, and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit www.wmt.com . Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” as defined under U.S. federal securities laws, including statements about the complementary nature of the acquired businesses and the financial benefits of these acquisitions to Wright. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current view of future performance, results, and trends. Forward-looking statements may be identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The reader should not place undue reliance on forward-looking statements. Such statements are made as of the date of this press release, and we undertake no obligation to update such statements after this date. Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements in this press release include failure to realize the anticipated benefits, in whole or in part, from the acquired businesses, a delay in the realization thereof, unexpected liabilities and/or erroneous financial estimates and projections for the acquired businesses, and potential sales dis-synergies during the integration process. Additional risks and uncertainties are discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012, and as may be supplemented in our Quarterly Reports on Form 10-Q). By way of example and without implied limitation, such risks and uncertainties include: failure to realize the anticipated benefits of the Biotech International acquisition in whole or in part, and unexpected liabilities and/or erroneous financial estimates and projections for the acquired business; failure to realize the anticipated financial and other benefits from the acquisition of BioMimetic Therapeutics, Inc. or a delay in realization thereof; failure to obtain, or a delay in obtaining, FDA approval of Augment Bone Graft, or a material limitation on the scope of such approval; lower than anticipated market acceptance of, or annual market demand for, Augment Bone Graft; failure to realize the anticipated benefits of the OrthoRecon divestiture to MicroPort in whole or in part, including unexpected liabilities and/or erroneous financial estimates and projections for the retained business; future actions of the United States Attorney's office, the FDA, the Department of Health and Human Services or other U.S. or foreign government authorities, including those resulting from increased scrutiny under the Foreign Corrupt Practices Act and similar laws, that could delay, limit or suspend our development, manufacturing, commercialization and sale of products, or result in seizures, injunctions, monetary sanctions or criminal or civil liabilities; failure to obtain the FDA or other regulatory clearances needed to market and sell our products; any actual or alleged breach of the Corporate Integrity Agreement to which we are subject through September 2015 which could expose us to significant liability including exclusion from Medicare, Medicaid and other federal healthcare programs, potential criminal prosecution, and civil and criminal fines or penalties; adverse outcomes in existing product liability litigation; new product liability claims; inadequate insurance coverage; the possibility of private securities litigation or shareholder derivative suits; demand for and market acceptance of our new and existing products; potentially burdensome tax measures; recently enacted healthcare laws and changes in product reimbursement which could generate downward pressure on our product pricing; lack of suitable business development opportunities; inability to capitalize on business development opportunities; product quality or patient safety issues; challenges to our intellectual property rights; geographic and product mix impact on our sales; our inability to retain key sales representatives, independent distributors and other personnel or to attract new talent; inventory reductions or fluctuations in buying patterns by wholesalers or distributors; inability to realize the anticipated benefits of restructuring initiatives; negative impact of the commercial and credit environment on us, our customers and our suppliers; and the potentially negative effect of our ongoing compliance enhancements on our relationships with customers and our ability to deliver timely and effective medical education, clinical studies, and new products. Contacts

Solana Surgical Frequently Asked Questions (FAQ)

  • Where is Solana Surgical's headquarters?

    Solana Surgical's headquarters is located at 6363 Poplar Ave, Memphis.

  • What is Solana Surgical's latest funding round?

    Solana Surgical's latest funding round is Acquired.

  • Who are the investors of Solana Surgical?

    Investors of Solana Surgical include Wright Medical Group.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.